Canakinumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Canakinumab: From Cryopyrin-Associated Periodic Syndrome (CAPS) to Hepatic Infarction
One-Sentence Summary
Canakinumab (Ilaris) is a fully human anti-IL-1β monoclonal antibody developed by Novartis, originally approved for cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). The TxGNN model predicts it may also be effective for Hepatic Infarction with a prediction score of 99.86%; however, currently no clinical trials and only 1 tangentially related publication support this specific direction, placing it at the lowest evidence tier (L5 — model prediction only, no actual studies).
⚠️ Note: While hepatic infarction ranks #1 by TxGNN score, TxGNN also predicts Canakinumab for Familial Mediterranean Fever (rank #6) with 7 clinical trials and 20 publications at L1 evidence. Reviewers are advised to consider the full ranked list in context.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cryopyrin-Associated Periodic Syndrome (CAPS) — inferred from published literature; Taiwan regulatory data not available |
| Predicted New Indication | Hepatic Infarction |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations (Taiwan) | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known published information, Canakinumab is a fully human IgG1/κ monoclonal antibody that selectively binds and neutralizes interleukin-1β (IL-1β), thereby suppressing downstream pro-inflammatory cascades mediated through IL-1 receptor type I (IL-1RI). This mechanism has been clinically validated across multiple IL-1β-driven autoinflammatory diseases, including CAPS, systemic juvenile idiopathic arthritis (sJIA), familial Mediterranean fever (FMF), TNF receptor-associated periodic syndrome (TRAPS), and hyperimmunoglobulinemia D syndrome/mevalonate kinase deficiency (HIDS/MKD).
The biological rationale for hepatic infarction rests on the known role of IL-1β in hepatic ischemia-reperfusion injury (IRI). Following hepatic vascular occlusion and reperfusion, IL-1β acts as a key amplifier of the sterile inflammatory cascade, promoting Kupffer cell activation, neutrophil recruitment, and hepatocyte apoptosis. Theoretically, neutralizing IL-1β could attenuate post-ischemic tissue damage. However, this mechanistic link is highly speculative — no direct preclinical or clinical studies have examined Canakinumab specifically in the context of hepatic infarction.
The TxGNN model assigned this prediction a high rank (score 99.86%), likely capturing indirect network relationships between Canakinumab’s IL-1β inhibition mechanism and hepatic inflammatory pathology rather than a direct clinical or mechanistic signal. The single literature item retrieved (PMID 37354546) concerns bempedoic acid in cardiovascular prevention and is not relevant to this indication, confirming the absence of a real evidence base.
Clinical Trial Evidence
Currently no related clinical trials registered for Canakinumab in hepatic infarction.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37354546 | 2023 | RCT | JAMA | Bempedoic acid vs. placebo for primary cardiovascular prevention in statin-intolerant patients without prior cardiovascular events. Not relevant to Canakinumab or hepatic infarction — retrieved by indirect cardiovascular query association. |
Safety Considerations
Please refer to the SmPC for safety information.
Taiwan TFDA SmPC label warnings and contraindications were not available in this evidence pack. Drug-drug interaction data query returned no results. Full safety evaluation requires TFDA label retrieval prior to any clinical consideration.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for Canakinumab in hepatic infarction is entirely model-derived (L5) with no supporting clinical trials or directly relevant literature. Although the IL-1β pathway is biologically involved in hepatic ischemia-reperfusion injury, this mechanistic link has not been validated in any preclinical or clinical study, making advancement beyond a speculative hypothesis premature.
To proceed, the following is needed:
- Preclinical studies (e.g., murine hepatic IRI models) evaluating IL-1β blockade in hepatic infarction to establish proof of concept
- Mechanism of action clarification specifically in the context of hepatic vascular injury
- Taiwan TFDA SmPC retrieval for complete safety profiling (warnings, contraindications)
- Drug-drug interaction assessment in hepatic disease populations
- Identification of a clinically plausible patient subgroup (e.g., post-transplant hepatic IRI with excessive inflammatory response) where IL-1β neutralization could offer benefit
- Prioritization recommendation: Redirect resources toward the FMF (rank #6, L1, 7 trials) and periodic fever syndrome (rank #5, L3, 19 publications) predictions, where the mechanistic basis is established and regulatory precedent exists in other jurisdictions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.